Marc Dunoyer

Marc became chief executive officer of Alexion, AstraZeneca’s Rare Disease group, in August 2021 following its acquisition in July. Marc previously served as executive director and chief financial officer of AstraZeneca since November 2013. Marc’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel, and GSK, has given him extensive industry experience. Marc joined AstraZeneca in 2013, serving as executive vice president, global product and portfolio strategy from June to October 2013. Prior to that, he served as global head of rare diseases at GSK and (concurrently) chairman, GSK Japan.

Marc earned his MBA from the Hautes Etudes Commerciales and a Bachelor of Law degree from Paris University.